Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1998; 31:1449-1459
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brieger, D.
Right arrow Articles by Topol, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brieger, D.
Right arrow Articles by Topol, E.

Heparin-induced thrombocytopenia

DB Brieger, KH Mak, K Kottke-Marchant, and EJ Topol

Department of Cardiology, Joseph J. Jacobs Center for Vascular Biology, The Cleveland Clinic Foundation, Ohio 44195, USA.

Heparin-induced thrombocytopenia (HIT) is a potentially serious complication of heparin therapy and is being encountered more frequently in patients with cardiovascular disease as use of anticoagulant therapy becomes more widespread. Our understanding of the pathophysiology of this immune-mediated condition has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most patients. New sensitive laboratory assays for the pathogenic antibody are now available and should permit an earlier, more reliable diagnosis, but their optimal application remains to be defined. For patients in whom HIT is diagnosed, immediate discontinuation of heparin infusions and elimination of heparin from all flushes and ports are mandatory. Further management of patients with HIT is problematic at present, as there are no readily available alternative anticoagulant agents in the United States with proven efficacy in acute coronary disease. The direct thrombin inhibitors appear to be the most promising alternatives to heparin, when continued use of heparin is contraindicated, and the results of several multicenter trials evaluating their application in patients with HIT are awaited.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
A. J Ansara, S. Arif, and R. D Warhurst
Weight-Based Argatroban Dosing Nomogram for Treatment of Heparin-Induced Thrombocytopenia
Ann. Pharmacother., January 1, 2009; 43(1): 9 - 18.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. P Keegan, E. M Gallagher, N. E Ernst, E. J Young, and E. W Mueller
Effects of Critical Illness and Organ Failure on Therapeutic Argatroban Dosage Requirements in Patients with Suspected or Confirmed Heparin-Induced Thrombocytopenia
Ann. Pharmacother., January 1, 2009; 43(1): 19 - 27.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
W. Kittisupamongkol
Incidence and Prognostic Significance of Thrombocytopenia in Patients Receiving Heparin Therapy
Arch Intern Med, October 27, 2008; 168(19): 2170 - 2170.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
K. W. Phillips, P. P. Dobesh, and S. T. Haines
Considerations in using anticoagulant therapy in special patient populations
Am. J. Health Syst. Pharm., August 1, 2008; 65(15_Supplement_7): S13 - S21.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. F. Merry
Focus on Thrombin: Alternative Anticoagulants
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260.
[Abstract] [PDF]


Home page
CirculationHome page
Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. S. Carr, A. Rayner, J. Ponte, and J. B. Desai
Off-Pump Coronary Artery Bypass Grafting in a Heparin-Induced Thrombocytopenia Type II Patient Using Hirudin
Ann. Thorac. Surg., February 1, 2005; 79(2): 696 - 698.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
P. Kumar, D. A. Hoppensteadt, M. M. Prechel, R. B. Deddish, and J. M. Walenga
Prevalance of Heparin-Dependent Platelet-Activating Antibodies in Preterm Newborns After Exposure to Unfractionated Heparin
Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 335 - 339.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
S. Suzuki, S. Sakamoto, M. Matsuo, C. Shimano, T. Kuroda, and T. Matsuo
Thrombotic Complications in Three Hemodialysis Patients With Heparin-Induced Thrombocytopenia Type I
Clinical and Applied Thrombosis/Hemostasis, January 1, 2004; 10(1): 81 - 84.
[Abstract] [PDF]


Home page
Crit Care NurseHome page
K. W. Cleveland
Argatroban: A New Treatment Option for Heparin-Induced Thrombocytopenia
Crit. Care Nurse, December 1, 2003; 23(6): 61 - 66.
[Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. Koster and T. Fischer
Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
J. R. De Palma
Delayed-Onset Heparin-Induced Thrombocytopenia
Ann Intern Med, November 4, 2003; 139(9): 790 - 790.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Collart, D. Derouck, F. Kerbaul, H. Feier, and T. G. Mesana
Regression of intracardiac heparin-induced thrombosis after aortic root surgery
Ann. Thorac. Surg., August 1, 2003; 76(2): 617 - 619.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
E. Pravinkumar and N. R. Webster
HIT/HITT and alternative anticoagulation: current concepts
Br. J. Anaesth., May 1, 2003; 90(5): 676 - 685.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. G Reichert, D. A MacGregor, E. H Kincaid, and S. Y Dolinski
Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia
Ann. Pharmacother., May 1, 2003; 37(5): 652 - 654.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. C. Vasquez, A. Vichiendilokkul, S. Mahmood, and F. A. Baciewicz Jr
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery
Ann. Thorac. Surg., December 1, 2002; 74(6): 2177 - 2179.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
S. K. Young
New Treatment Options for Heparin-Induced Thrombocytopenia
Journal of Pharmacy Practice, August 1, 2002; 15(4): 305 - 317.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
L. G. Y. Claeys
Lethal Heparin-Associated Pulmonary Embolism: Case Reports
Angiology, July 1, 2002; 53(4): 475 - 478.
[Abstract] [PDF]


Home page
CirculationHome page
J. E. Tcheng, D. J. Kereiakes, A. M. Lincoff, B. S. George, N. S. Kleiman, D. C. Sane, D. B. Cines, R. E. Jordan, M. A. Mascelli, M. A. Langrall, et al.
Abciximab Readministration: Results of the ReoPro Readministration Registry
Circulation, August 21, 2001; 104(8): 870 - 875.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. E. Lewis, D. E. Wallis, S. D. Berkowitz, W. H. Matthai, J. Fareed, J. M. Walenga, J. Bartholomew, R. Sham, R. G. Lerner, Z. R. Zeigler, et al.
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
Circulation, April 10, 2001; 103(14): 1838 - 1843.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. E. Wallis, R. Quintos, W. Wehrmacher, and H. Messmore
Safety of Warfarin Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
Chest, November 1, 1999; 116(5): 1333 - 1338.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. F. Vazquez-Jimenez, U. Janssens, B. Sellhaus, B. Hermanns, W. Huegel, P. Hanrath, and B. J. Messmer
THROMBOSIS OF A MITRAL VALVE PROSTHESIS IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II
J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 751 - 753.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
D. E. Wallis, B. E. Lewis, H. L. Messmore, R. Pifarre, and J. M. Walenga
Inadequacy of Current Prevention Strategies for Heparin-Induced Thrombocytopenia
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S16 - S20.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
J. Fareed, J. M. Walenga, D. A. Hoppensteadt, W. P. Jeske, S. Ahmad, H. Lietz, R. McKenna, H. L. Messmore, and S. Haas
Soluble Adhesion Molecules in the HIT Syndrome: Pathophysiologic Role and Therapeutic Modulation
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S38 - S44.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
P. J. Zed, J. E. Tisdale, and S. Borzak
Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes
Arch Intern Med, September 13, 1999; 159(16): 1849 - 1857.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. W. McClure, S. D. Berkowitz, R. Sparapani, R. Tuttle, N. S. Kleiman, L. G. Berdan, A. M. Lincoff, J. Deckers, R. Diaz, K. R. Karsch, et al.
Clinical Significance of Thrombocytopenia During a Non–ST-Elevation Acute Coronary Syndrome : The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience
Circulation, June 8, 1999; 99(22): 2892 - 2900.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement